Literature DB >> 6585426

Expression of MY7 antigen on myeloid precursor cells.

J D Griffin, J Ritz, R P Beveridge, J M Lipton, J F Daley, S F Schlossman.   

Abstract

A murine monoclonal antibody (anti-MY7) has been developed that detects an antigen expressed by 6% of normal human bone marrow cells, including approximately 40% of myeloid colony-forming cells (CFU-C). The number of bone marrow cells and CFU-C expressing MY7 is significantly increased in regenerating bone marrow, but less than 5% of peripheral blood CFU-C express the MY7 antigen. Erythroid precursors are MY7 negative from peripheral blood and bone marrow. Thymidine suicide studies indicate that CFU-C in S-phase tend to be MY7 positive while CFU-C not in S-phase are MY7 negative. MY7 expression thus appears to identify a fraction of CFU-C that is actively proliferating.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6585426     DOI: 10.1002/stem.5530010106

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  11 in total

1.  c-Maf interacts with c-Myb to regulate transcription of an early myeloid gene during differentiation.

Authors:  S P Hedge; A Kumar; C Kurschner; L H Shapiro
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

2.  Molecular cloning, expression, and chromosomal localization of the gene encoding a human myeloid membrane antigen (gp150).

Authors:  A T Look; S C Peiper; M B Rebentisch; R A Ashmun; M F Roussel; R S Lemons; M M Le Beau; C M Rubin; C J Sherr
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-dependent metallopeptidase family.

Authors:  Q Wu; J M Lahti; G M Air; P D Burrows; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 4.  CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature.

Authors:  C H Dunphy; L J Gardner; J L Manes; C S Bee; K Taysi
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

5.  Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung.

Authors:  M Mabry; J A Speak; J D Griffin; R A Stahel; S D Bernal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

6.  Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N.

Authors:  A T Look; R A Ashmun; L H Shapiro; S C Peiper
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Transfer and expression of the gene encoding a human myeloid membrane antigen (gp150).

Authors:  A T Look; S C Peiper; M B Rebentisch; R A Ashmun; M F Roussel; C W Rettenmier; C J Sherr
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Authors:  K D Sabbath; E D Ball; P Larcom; R B Davis; J D Griffin
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

9.  Expression of aminopeptidase N (CD13) in mesenchymal tumors.

Authors:  G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

10.  Demonstration of CD13/aminopeptidase N on synovial fluid T cells from patients with different forms of joint effusions.

Authors:  D Riemann; A Schwachula; M Hentschel; J Langner
Journal:  Immunobiology       Date:  1993-01       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.